SARS CoV 2 News and Research

RSS

Novel face mask can diagnose Covid-19 in 90 minutes

Engineers at MIT and Harvard University have designed a novel face mask that can diagnose the wearer with Covid-19 within about 90 minutes. The masks are embedded with tiny, disposable sensors that can be fitted into other face masks and could also be adapted to detect other viruses.

28 Jun 2021

UK study finds SARS-CoV-2 antibodies in domestic cats and dogs

Researchers analyzed sera from pet cats and dogs and found them to have developed antibodies against the virus later on during the COVID-19 pandemic. These findings suggest that viral prevalence among the human populations could have led to the pets becoming infected.

28 Jun 2021

Study associates higher antibody titers with naïve B cells post-mRNA vaccination

Researchers compared peripheral blood mononuclear cells in people with high and low antibody titers after two doses of the Pfizer/BioNTech (BNT162b2) mRNA vaccine. They found a positive correlation between naïve B cells present before vaccination and high antibody titers.

28 Jun 2021

What have been the main drivers of COVID-19's rapid spread in Brazil?

New research suggests that if a lockdown had been imposed earlier on in superspreader cities like São Paulo, mandatory road traffic restrictions had been enforced, and ICU beds had been allocated more equitably across geographical regions, Brazil’s experience of the COVID-19 pandemic might have been mitigated.

28 Jun 2021

Study finds minimal SARS-CoV-2 viral load in vaginal secretions

The virus has also been observed to be present in blood, urine, feces, and tears, though not in semen. Vaginal secretions have not been consistently shown to be positive for the virus in most studies. The authors of a new study in the Journal of Clinical Medicine affirm that the presence of the virus in the vagina is rare, irrespective of pregnancy.

28 Jun 2021

Resting heart rate variability predicts emotional resilience during COVID-19 restrictions

An interesting new study available as a preprint on the medRxiv* server suggests that vagally-mediated heart rate variability (vmHRV) is a physiological marker of resilience to stress by indicating how well an individual handles the emotions when faced with changes in the surroundings.

28 Jun 2021

Could microalgae-derived antiviral compounds combat SARS-CoV-2 and other viruses?

A new review article published in the journal Antibiotics reports the presence of a large number of bioactive compounds in microalgae that target chemical structures present only in their structure.

28 Jun 2021

Vaccines and drugs must be adapted to combat emerging SARS-CoV-2 variants, says study

A new review of the emerging variants of concern (VOCs) of the SARS-CoV-2, which has caused the COVID-19 pandemic, shows that there is a major need to constantly re-evaluate the utility of existing therapeutics and vaccines against the virus and to develop new ones.

28 Jun 2021

Tocilizumab and sarilumab shown to be effective in critical COVID-19

A new study, released as a preprint on the medRxiv* server, describes how a team of researchers from the University Medical Center Utrecht in the Netherlands explored the efficacy of four monoclonal antibodies that antagonize powerful pro-inflammatory pathways. The team sought to determine which were useful in treating critically ill COVID-19 patients on organ support.

28 Jun 2021

An affordable, scalable and highly sensitive virus-genome-based testing approach

Aiming to reduce human suffering, economic costs, and restrictions on personal freedom caused by COVID-19 to a minimum, researchers from Germany and Austria proposed an alternative method - efficient population-based genome-based testing.

28 Jun 2021

Oxford-AstraZeneca COVID-19 vaccine induces robust T cell-based immunity

A recent study conducted by an international team of scientists has revealed that the Oxford-AstraZeneca coronavirus disease 2019 (COVID-19) vaccine, AZD1222, is capable of inducing strong spike-specific CD4+ T cell helper type 1 (Th1) and CD8+ T-cell responses in vaccinated individuals. A detailed description of AZD1222-induced cellular immunity is currently available on the medRxiv* preprint server.

28 Jun 2021

Why SARS-CoV-2 delta variant is more infectious

German experts recently explained why the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta variant is more infectious and pathogenic than its ancestor. By conducting a series of in vitro experiments, they have revealed that increased ability to induce cell-to-cell fusion (syncytia) and reduced susceptibility to vaccine and infection-induced antibodies make the delta variant more infectious than previously circulating variants. The study is currently available on the bioRxiv* preprint server.

28 Jun 2021

An oral pill for COVID-19? Molnupiravir shows promise

Recently, researchers reported molnupiravir as the first oral and direct-acting antiviral that is highly effective at reducing SARS-CoV-2 levels.

27 Jun 2021

Swedish study reveals how long immunity lasts after mild COVID

As a result of the ongoing pandemic of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated disease, the coronavirus disease 2019 (COVID-19), the global public health at risk has never been more dire.

27 Jun 2021

Why is staying active important during the COVID-19 pandemic?

Working from home is no excuse to stop exercising. New research led by Akira Ogami from the University of Occupational and Environmental Health in Japan confirms that regular exercise is needed in maintaining good physical and mental health during the COVID-19 pandemic. Workers who allocated time towards exercise or some form of physical activity reported a higher health-related quality of life than people who did not.

27 Jun 2021

Oxford study sheds light on level of antibodies needed to protect against COVID-19 symptoms

Researchers in the UK have reported on the relationship between humoral (antibody) responses and protection against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) following immunization with AstraZeneca’s ChAdOx1 vaccine.

27 Jun 2021

Lambda lineage of SARS-CoV-2 has potential to become variant of concern

Researchers have described the first reported infection with the C.37 (Lambda) lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Southern Brazil.

27 Jun 2021

Structural studies of SARS-CoV-2 spike protein reveal new properties of Alpha and Beta variants

New SARS-CoV-2 variants are spreading rapidly, and there are fears that current COVID-19 vaccines won't protect against them.

25 Jun 2021

SARS-CoV-2 virus sequences could be identified from hospital surface swabs

A new study by UC Davis researchers confirms the low likelihood that SARS-CoV-2 contamination on hospital surfaces is infectious.

25 Jun 2021

Novel biosensor offers rapid quantitative variant of concern-independent serology for SARS-CoV-2

Even as herculean efforts are being made to extend the reach of vaccination against COVID-19 to all the regions of the world, there is a dire need for rapid and sensitive tests to assess the antibody response to the various vaccines used and to monitor antibody titers over time. A new preprint describes a new approach to this problem which could be applied to other molecules of interest as well, both in laboratories and at the point of care.

25 Jun 2021

SARS CoV 2 News and Research

Novel face mask can diagnose Covid-19 in 90 minutes

UK study finds SARS-CoV-2 antibodies in domestic cats and dogs

Study associates higher antibody titers with naïve B cells post-mRNA vaccination

What have been the main drivers of COVID-19's rapid spread in Brazil?

Study finds minimal SARS-CoV-2 viral load in vaginal secretions

Resting heart rate variability predicts emotional resilience during COVID-19 restrictions

Could microalgae-derived antiviral compounds combat SARS-CoV-2 and other viruses?

Vaccines and drugs must be adapted to combat emerging SARS-CoV-2 variants, says study

Tocilizumab and sarilumab shown to be effective in critical COVID-19

An affordable, scalable and highly sensitive virus-genome-based testing approach

Oxford-AstraZeneca COVID-19 vaccine induces robust T cell-based immunity

Why SARS-CoV-2 delta variant is more infectious

An oral pill for COVID-19? Molnupiravir shows promise

Swedish study reveals how long immunity lasts after mild COVID

Why is staying active important during the COVID-19 pandemic?

Oxford study sheds light on level of antibodies needed to protect against COVID-19 symptoms

Lambda lineage of SARS-CoV-2 has potential to become variant of concern

Structural studies of SARS-CoV-2 spike protein reveal new properties of Alpha and Beta variants

SARS-CoV-2 virus sequences could be identified from hospital surface swabs

Novel biosensor offers rapid quantitative variant of concern-independent serology for SARS-CoV-2

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News